Guggenheim Maintains Buy on Zenas BioPharma, Raises Price Target to $55

Guggenheim analyst Yatin Suneja has maintained a Buy rating on Zenas BioPharma (NASDAQ: ZBIO) and increased the price target from $45 to $55. This adjustment reflects a positive outlook for the company's performance in the market.